Final Days to Register!
There has been a significant increase in the level of activity and attention being paid to the development of therapeutics for neglected diseases over the past five years, but there are still considerable challenges in the road ahead. Diseases in the developed world receive a disproportional investment because of the commercial potential from large markets and the ability to pay for such treatment. Innovative approaches are being developed to stimulate interest and provide incentives for companies and other researchers to work on finding new therapeutics for diseases prevalent in developing countries. Almost all work in this field will be based on collaborations of one type or another, during discovery, drug evaluation or, when successful, delivery of treatments. This forum is designed to bring together many of the major stakeholders addressing these problems, in order to examine and discuss strategies and best practices for solving the major challenges that prevent faster and more effective solutions.
Coverage Includes:
Strategies to Improve Collaboration with Academics
Ways to Improve the Contributions of Companies in Developing Countries
Leveraging Opportunities in Developed Markets to Support Neglected Disease Products
Development of Vaccines, Anti-Virals and Other Anti-Infectives
Strategies for Sharing Intellectual Property while Still Protecting It
Best Practices for Collaboration with Developing Countries
Different Models for Funding and Incentives for Research and Development
Addressing the Challenge of Delivery in the Face of Limited Health Infrastructure
Distinguished Faculty:
Beatrice Sequin, Ph.D., Assistant Professor, Leslie Dan Faculty of Pharmacy; Program Leader, Commercialization in Emerging Economies, McLaughlin-Rotman Centre for Global Health, University Health and University of Toronto
Brigitta Tadmore, Ph.D., Vice President, Global Head, Diversity & Inclusion and Health Policy, Novartis Institute for BioMedical Research
Dale A. Cumming, Ph.D., Director, Scientific Evaluation, International Consortium on Anti-virals; Acton Biotech Consulting
Debra Hanna, Ph.D., Senior Principal Scientist, Antibacterial Research Unit, Pfizer, Inc.
Denice Spero, Ph.D., Research Professor & Co-Director, Institute for Immunology and Informatics, University of Rhode Island
Gustavo Dayan, Ph.D., Director, Clinical Development, Sanofi Pasteur
Jacqueline B. Fine, Ph.D., Associate Director, Asset Management and Out-licensing, External Scientific Affairs, Merck Research Laboratories
Jan Gheuens, M.D., Ph.D., Senior Program Officer, Tuberculosis, Global Health Program, Infectious Diseases, Bill and Melinda Gates Foundation
John Garrett, Ph.D., Co-CEO, Glycosyn, Inc.
Kate Marusina, Ph.D., Manager, Industry Alliances, CTSC, University of California, Davis
Ken Gustavsen, Ph.D., M.B.A., Director, Global Product Donations, Office of Corporate Responsibility, Merck
Lydia Pan, Ph.D., Director, Science Policy, Pfizer, Inc.
Michael Cynamon, M.D., Department of Medicine, SUNY Upstate Medical University
Muhammad Yunus, Professor, Founder & Managing Director, Grameen Bank; Chairman, Grameen Healthcare Trust; 2006 Nobel Peace Prize Laureate
Nicholas Cammack, Ph.D., Senior Vice President & Head, Diseases for the Developing World, Medicines Development Campus, GlaxoSmithKline SL (Spain)
Patrick Nef, Ph.D., Chief Business Officer, Medicines for Malaria Venture (MMV)
Rashmi H. Barbhaiya, Ph.D., CEO & Managing Director, Advinus Therapeutics Pvt Ltd, A Tata Enterprise
Agenda: Day 1 | Day 2
For more details on the conference, please contact:
Phillips Kuhl
President
Cambridge Healthtech Institute
T: (+1) 781-972-5410
E: pkuhl@healthtech.com
For partnering and sponsorship information, please contact:
Arnie Wolfson
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: awolfson@healthtech.com